REG - Futura Medical PLC - Patent notice of allowance granted for the US

Futura MedicalAnnouncement

05/02/2026 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260205:nRSE7837Ra&default-theme=true

RNS Number : 7837R  Futura Medical PLC  05 February 2026

5 February 2026

Futura Medical plc

("Futura", "the Group" or the "Company")

Patent notice of allowance granted for MED3000 (Eroxon) in the US

 

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and
that specialises in the development and global commercialisation of innovative
and clinically proven sexual health products, announces that it has been
granted notice of allowance of its US continuation patent (application number
19/252084) which will provide additional protection for Eroxon® (including
formulation derivatives such as the Eroxon® Intense formulation) and women's
product WSD4000  (currently in development) until 2040 in the US.

 

The new patent contains formulation claims that means the Company is confident
that the granting of the patent (which is now expected before the end of Q2
2026) will trigger a US patent milestone payment of US$2.5 million under the
terms of the Company's existing license agreement with Haleon.

 

This allowance adds to the Company's existing patent protection in Europe,
Hong Kong, Taiwan and China, further consolidating its global IP. Other
applications in additional markets remain pending.

Alex Duggan, CEO of Futura, commented: "The grant of this patent in the US
will be a major milestone for Futura and is one of our key objectives for
2026. The receipt of the milestone payment will secure our cash runway to
support current development opportunities. The United States is the largest
global market for erectile dysfunction so importantly, this patent grant will
provide an enhanced competitive position for both current and potential new
formulations of Eroxon; in addition it will provide protection in the US for
our development product WSD4000."

 

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014
as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019.

Contacts:

 Futura Medical plc                          Alex Duggan                                             investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                             Chief Executive Officer

                                                       +44 (0)1483 685 670
                                             Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                             Finance Director and COO

 Panmure Liberum                             Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser

 and Broker

 Turner Pope Investments (TPI) Ltd - Broker  Guy McDougall, Andrew Thacker                           +44 (0) 20 3657 0050

 Alma Strategic Communications               Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters        +44 (0)20 3405 0205

                                                                                                     futura@almastrategic.com

 

Notes to Editors:

 

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and development products WSD4000
and Eroxon(®) Intense. Our core strength lies in the research, development
and commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. Erectile Dysfunction
("ED") impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. Around 60% of women experience at least one
symptom of sexual dysfunction, and only one in four women seek professional
help, and remain chronically underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection in ten minutes, addresses significant unmet needs in the ED market.
Eroxon(®) has been nominated for a number of healthcare industry awards and
has won two to-date.

 

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

 

WSD4000 is a topical treatment designed for the symptoms of impaired sexual
response and function in women. There is currently no regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal and lubrication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSSUFULEMSELE



            Copyright 2019 Regulatory News Service, all rights reserved